bupivacaine S75:R25 plus 8% glucose — Competitive Intelligence Brief

bupivacaine S75:R25 plus 8% glucose (bupivacaine S75:R25 plus 8% glucose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesiology.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesiology Small molecule

Target snapshot

bupivacaine S75:R25 plus 8% glucose (bupivacaine S75:R25 plus 8% glucose) — Cristália Produtos Químicos Farmacêuticos Ltda.. Bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupivacaine S75:R25 plus 8% glucose TARGET	bupivacaine S75:R25 plus 8% glucose	Cristália Produtos Químicos Farmacêuticos Ltda.	phase 3	Local anesthetic	Voltage-gated sodium channels
Lidocaine patch 1.8%	Lidocaine patch 1.8%	Scilex Pharmaceuticals, Inc.	marketed	Local anesthetic	Voltage-gated sodium channels
Lamotrigine + Aripiprazole	Lamotrigine + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Anticonvulsant/mood stabilizer + atypical antipsychotic combination	Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole)
Bupivacaine Hydrochloride combined with dexamethasone	Bupivacaine Hydrochloride combined with dexamethasone	Zhejiang Cancer Hospital	marketed	Local anesthetic with corticosteroid adjuvant	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
oral suzetrigine	oral suzetrigine	University of Louisville	marketed	Selective sodium channel blocker	Voltage-gated sodium channels (Nav)
Oral Zonisamide Therapy	Oral Zonisamide Therapy	Affiliated Hospital of Nantong University	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Bupivacaine 20cc	Bupivacaine 20cc	Hospital for Special Surgery, New York	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class